967 related articles for article (PubMed ID: 17786271)
1. Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.
Bhuvaneswari R; Gan YY; Yee KK; Soo KC; Olivo M
Int J Mol Med; 2007 Oct; 20(4):421-8. PubMed ID: 17786271
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Yee KK; Soo KC; Olivo M
Int J Mol Med; 2005 Dec; 16(6):993-1002. PubMed ID: 16273277
[TBL] [Abstract][Full Text] [Related]
3. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Photochem Photobiol Sci; 2007 Dec; 6(12):1275-83. PubMed ID: 18046482
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and photodynamic therapy with hypericin in a human NPC murine tumor model.
Du HY; Bay BH; Olivo M
Int J Oncol; 2003 May; 22(5):1019-24. PubMed ID: 12684667
[TBL] [Abstract][Full Text] [Related]
5. Hypericin-photodynamic therapy (PDT) using an alternative treatment regime suitable for multi-fraction PDT.
Thong PS; Watt F; Ren MQ; Tan PH; Soo KC; Olivo M
J Photochem Photobiol B; 2006 Jan; 82(1):1-8. PubMed ID: 16203156
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
Ferrario A; von Tiehl KF; Rucker N; Schwarz MA; Gill PS; Gomer CJ
Cancer Res; 2000 Aug; 60(15):4066-9. PubMed ID: 10945611
[TBL] [Abstract][Full Text] [Related]
8. Photoactivation of hypericin down-regulates glutathione S-transferase activity in nasopharyngeal cancer cells.
Du HY; Olivo M; Tan BK; Bay BH
Cancer Lett; 2004 Apr; 207(2):175-81. PubMed ID: 15072826
[TBL] [Abstract][Full Text] [Related]
9. Hypericin-mediated photodynamic therapy induces lipid peroxidation and necrosis in nasopharyngeal cancer.
Du HY; Olivo M; Tan BK; Bay BH
Int J Oncol; 2003 Nov; 23(5):1401-5. PubMed ID: 14532982
[TBL] [Abstract][Full Text] [Related]
10. In vivo photodynamic activity of hypericin in transitional cell carcinoma bladder tumors.
Zupkó I; Kamuhabwa AR; D'Hallewin MA; Baert L; De Witte PA
Int J Oncol; 2001 May; 18(5):1099-105. PubMed ID: 11295062
[TBL] [Abstract][Full Text] [Related]
11. High expression of GADD-45alpha and VEGF induced tumor recurrence via upregulation of IL-2 after photodynamic therapy using NPe6.
Ohtani K; Usuda J; Ichinose S; Ishizumi T; Hirata T; Inoue T; Maehara S; Imai K; Kubota M; Tsunoda Y; Yamada M; Tsutsui H; Yamada K; Kuroiwa Y; Furukawa K; Okunaka T; Kato H
Int J Oncol; 2008 Feb; 32(2):397-403. PubMed ID: 18202762
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer.
Solban N; Selbo PK; Sinha AK; Chang SK; Hasan T
Cancer Res; 2006 Jun; 66(11):5633-40. PubMed ID: 16740700
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
[TBL] [Abstract][Full Text] [Related]
14. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells.
Tirand L; Frochot C; Vanderesse R; Thomas N; Trinquet E; Pinel S; Viriot ML; Guillemin F; Barberi-Heyob M
J Control Release; 2006 Mar; 111(1-2):153-64. PubMed ID: 16423422
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
Ferrario A; Fisher AM; Rucker N; Gomer CJ
Cancer Res; 2005 Oct; 65(20):9473-8. PubMed ID: 16230411
[TBL] [Abstract][Full Text] [Related]
16. Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy.
Chen B; Zupkó I; de Witte PA
Int J Oncol; 2001 Apr; 18(4):737-42. PubMed ID: 11251168
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Hypocrellin B in a human bladder tumor model in experimental photodynamic therapy: biodistribution, light dose and drug-light interval effects.
Chin W; Lau W; Cheng C; Olivo M
Int J Oncol; 2004 Sep; 25(3):623-9. PubMed ID: 15289863
[TBL] [Abstract][Full Text] [Related]
18. Differential up-regulation of metallothionein isoforms in well-differentiated nasopharyngeal cancer cells in vitro by photoactivated hypericin.
Du HY; Li Y; Olivo M; Yip GW; Bay BH
Oncol Rep; 2006 Dec; 16(6):1397-402. PubMed ID: 17089067
[TBL] [Abstract][Full Text] [Related]
19. Hypericin-mediated photodynamic therapy elicits differential interleukin-6 response in nasopharyngeal cancer.
Du H; Bay BH; Mahendran R; Olivo M
Cancer Lett; 2006 Apr; 235(2):202-8. PubMed ID: 15935550
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy of transitional cell carcinoma multicellular tumor spheroids with hypericin.
Kamuhabwa AA; Huygens A; De Witte PA
Int J Oncol; 2003 Nov; 23(5):1445-50. PubMed ID: 14532989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
